Oculus Innovative Wt (OCLSW) 0.24 $OCLSW Oculus
Post# of 273322
Posted On: 09/22/2016 5:17:59 AM
Oculus Innovative Wt (OCLSW) 0.24 $OCLSW
Oculus Innovative Sciences to Present at the Third Annual Growth Capital Expo MicroCap Investor Conference in Las Vegas
GlobeNewswire - Wed Apr 27, 3:05AM CDT
Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) (NASDAQ:OCLSW), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced that Jim Schutz, the company's CEO, will present a corporate overview and business update at the Third Annual Growth Capital Expo MicroCap Investor Conference, to be held on May 3-5, 2016 at Caesars Palace in Las Vegas. The Oculus presentation is scheduled on Wednesday, May 4, 2016, at 10:00 am PDT, with a breakout session to immediately follow.
OCLSW: 0.24 (-0.02), OCLS: 4.08 (-0.03)
Oculus Innovative Sciences Receives European Approval to Market Sinudox(TM) Indicated for Use in Nasal Irrigation
GlobeNewswire - Wed Apr 13, 3:05AM CDT
Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) (NASDAQ:OCLSW), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced the issuance of a new CE Mark in Europe for Microcyn(R)-based Sinudox(TM) solution, a formulation intended for nasal irrigation including the moistening of cuts, abrasions and lacerations located in the nasal cavity.
OCLSW: 0.24 (-0.02), OCLS: 4.08 (-0.03)
Oculus Innovative Sciences Reports Financial Results for the Second Quarter of Fiscal Year 2016
GlobeNewswire - Thu Nov 05, 3:05PM CST
Total Revenue of $4.1 Million Increased 24%--Led by 64% Increase in Product Revenue--Driven by Growth in U.S. Dermatology Sales
OCLSW: 0.24 (-0.02), OCLS: 4.08 (-0.03)
Oculus Innovative Sciences Announces Fiscal Second Quarter 2016 Financial Results and Conference Call
GlobeNewswire - Thu Oct 22, 5:05AM CDT
Oculus Innovative Sciences, Inc. (NASDAQ:OCLS), tradable warrants (NASDAQ:OCLSW) today announced that the financial results for its fiscal second quarter 2016, ended September 30, 2015, will be released after the U.S. markets close on November 5, 2015. The earnings release will be followed by a conference call at 1:30 p.m. PT on November 5, 2015, to discuss fiscal second quarter results.
OCLSW: 0.24 (-0.02), OCLS: 4.08 (-0.03)
Oculus Innovative Sciences Announces Preliminary Results for Its 2015 Annual Meeting of Stockholders
GlobeNewswire - Fri Sep 11, 5:30PM CDT
Oculus Innovative Sciences, Inc. (NASDAQ:OCLS), tradeable warrants (NASDAQ:OCLSW) today announced that the four proposals presented in its annual meeting proxy statement have, through September 10, 2015, received the affirmative vote of more than a majority of Oculus' shares of common stock represented or present at the 2015 annual meeting of stockholders.
OCLSW: 0.24 (-0.02), OCLS: 4.08 (-0.03)
Oculus Innovative Sciences Regains Compliance With NASDAQ Minimum Bid Price Rule
GlobeNewswire - Thu Jun 18, 5:00AM CDT
Oculus Innovative Sciences, Inc. (Nasdaq:OCLS) (Nasdaq:OCLSW), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced that it received a formal determination letter from The NASDAQ Stock Market LLC ("NASDAQ"
notifying the company that it is now compliant with the minimum bid price requirement for continued listing on the NASDAQ Capital Market and is no longer subject to delisting at this time. The NASDAQ staff has determined that for the 10 consecutive business days, from June 3, 2015, to June 16, 2015, the closing bid price of the company's common stock has been at $1.00 per share or greater.
OCLSW: 0.24 (-0.02), OCLS: 4.08 (-0.03)
Oculus Innovative Sciences Announces Sale of 1.65 Million Shares of Ruthigen Stock for $4.5 Million in Non-Dilutive Funding
GlobeNewswire - Tue Jun 16, 5:00AM CDT
-- Ruthigen/Pulmatrix merger closed on June 15, 2015, enabling Oculus' sale of Ruthigen shares to close on or before June 18, 2015
OCLSW: 0.24 (-0.02), OCLS: 4.08 (-0.03)
Oculus Innovative Sciences concludes public offering of common stock and warrants
M2 - Wed Jan 28, 4:21AM CST
Pharmaceutical company Oculus Innovative Sciences (Nasdaq:OCLS) (Nasdaq:OCLSW) disclosed on Tuesday that its has raised gross proceeds from its public offering, including the underwriters' partial exercise of the over-allotment option, of approximately USD6.3m.
OCLSW: 0.24 (-0.02), OCLS: 4.08 (-0.03)
Oculus Innovative Sciences to Present at the Third Annual Growth Capital Expo MicroCap Investor Conference in Las Vegas
GlobeNewswire - Wed Apr 27, 3:05AM CDT
Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) (NASDAQ:OCLSW), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced that Jim Schutz, the company's CEO, will present a corporate overview and business update at the Third Annual Growth Capital Expo MicroCap Investor Conference, to be held on May 3-5, 2016 at Caesars Palace in Las Vegas. The Oculus presentation is scheduled on Wednesday, May 4, 2016, at 10:00 am PDT, with a breakout session to immediately follow.
OCLSW: 0.24 (-0.02), OCLS: 4.08 (-0.03)
Oculus Innovative Sciences Receives European Approval to Market Sinudox(TM) Indicated for Use in Nasal Irrigation
GlobeNewswire - Wed Apr 13, 3:05AM CDT
Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) (NASDAQ:OCLSW), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced the issuance of a new CE Mark in Europe for Microcyn(R)-based Sinudox(TM) solution, a formulation intended for nasal irrigation including the moistening of cuts, abrasions and lacerations located in the nasal cavity.
OCLSW: 0.24 (-0.02), OCLS: 4.08 (-0.03)
Oculus Innovative Sciences Reports Financial Results for the Second Quarter of Fiscal Year 2016
GlobeNewswire - Thu Nov 05, 3:05PM CST
Total Revenue of $4.1 Million Increased 24%--Led by 64% Increase in Product Revenue--Driven by Growth in U.S. Dermatology Sales
OCLSW: 0.24 (-0.02), OCLS: 4.08 (-0.03)
Oculus Innovative Sciences Announces Fiscal Second Quarter 2016 Financial Results and Conference Call
GlobeNewswire - Thu Oct 22, 5:05AM CDT
Oculus Innovative Sciences, Inc. (NASDAQ:OCLS), tradable warrants (NASDAQ:OCLSW) today announced that the financial results for its fiscal second quarter 2016, ended September 30, 2015, will be released after the U.S. markets close on November 5, 2015. The earnings release will be followed by a conference call at 1:30 p.m. PT on November 5, 2015, to discuss fiscal second quarter results.
OCLSW: 0.24 (-0.02), OCLS: 4.08 (-0.03)
Oculus Innovative Sciences Announces Preliminary Results for Its 2015 Annual Meeting of Stockholders
GlobeNewswire - Fri Sep 11, 5:30PM CDT
Oculus Innovative Sciences, Inc. (NASDAQ:OCLS), tradeable warrants (NASDAQ:OCLSW) today announced that the four proposals presented in its annual meeting proxy statement have, through September 10, 2015, received the affirmative vote of more than a majority of Oculus' shares of common stock represented or present at the 2015 annual meeting of stockholders.
OCLSW: 0.24 (-0.02), OCLS: 4.08 (-0.03)
Oculus Innovative Sciences Regains Compliance With NASDAQ Minimum Bid Price Rule
GlobeNewswire - Thu Jun 18, 5:00AM CDT
Oculus Innovative Sciences, Inc. (Nasdaq:OCLS) (Nasdaq:OCLSW), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced that it received a formal determination letter from The NASDAQ Stock Market LLC ("NASDAQ"
notifying the company that it is now compliant with the minimum bid price requirement for continued listing on the NASDAQ Capital Market and is no longer subject to delisting at this time. The NASDAQ staff has determined that for the 10 consecutive business days, from June 3, 2015, to June 16, 2015, the closing bid price of the company's common stock has been at $1.00 per share or greater. OCLSW: 0.24 (-0.02), OCLS: 4.08 (-0.03)
Oculus Innovative Sciences Announces Sale of 1.65 Million Shares of Ruthigen Stock for $4.5 Million in Non-Dilutive Funding
GlobeNewswire - Tue Jun 16, 5:00AM CDT
-- Ruthigen/Pulmatrix merger closed on June 15, 2015, enabling Oculus' sale of Ruthigen shares to close on or before June 18, 2015
OCLSW: 0.24 (-0.02), OCLS: 4.08 (-0.03)
Oculus Innovative Sciences concludes public offering of common stock and warrants
M2 - Wed Jan 28, 4:21AM CST
Pharmaceutical company Oculus Innovative Sciences (Nasdaq:OCLS) (Nasdaq:OCLSW) disclosed on Tuesday that its has raised gross proceeds from its public offering, including the underwriters' partial exercise of the over-allotment option, of approximately USD6.3m.
OCLSW: 0.24 (-0.02), OCLS: 4.08 (-0.03)
(0)
(0)